Simona King - 28 Jul 2023 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role: Chief Financial Officer
Signature: /s/ Edgar Cale, Attorney-in-Fact
Issuer symbol: PASG
Transactions as of: 28 Jul 2023
Net transactions value: -$10,079
Form type: 4
Filing time: 01 Aug 2023, 16:36:49 UTC
Previous filing: 20 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PASG	Common Stock	Options Exercise	$0	+31,250	+745%	$0.000000	35,447	28 Jul 2023	Direct	F1
transaction	PASG	Common Stock	Sale	$10,079	-11,453	-32%	$0.8800	23,994	28 Jul 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PASG	Restricted Stock Units	Options Exercise	$0	-31,250	-100%	$0.000000^*	0	28 Jul 2023	Common Stock	31,250		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3	Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer.